Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate In Animal Eyes in Contrast With Vigabatrin
Portfolio Pulse from Benzinga Newsdesk
Ovid Therapeutics presented pre-clinical study results showing that their drug OV329 does not accumulate in animal eyes, unlike vigabatrin. This suggests a differentiated safety and efficacy profile. A Phase 1 trial is on track for completion in late 2024.
September 26, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ovid Therapeutics' pre-clinical study results indicate that OV329 does not accumulate in animal eyes, unlike vigabatrin, suggesting a better safety profile. This could positively impact Ovid's stock as it progresses to Phase 1 trials.
The study results suggest OV329 has a better safety profile compared to vigabatrin, which could lead to positive investor sentiment. The ongoing Phase 1 trial adds to the potential for future success, likely boosting Ovid's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100